| Cancer |
|
" Do not follow where the path may lead. Go instead where there is no path and leave a trail." Ralph Waldo Emerson | |
![]() |
|


















| Cancer | ARCHIVES The following information presented below is relevant to Mediscience Technology and has been included in our archive section. 8-K filing accepted for Feb 18, 2004 Click here. 8-K filing accepted for Feb 2, 2004 Click here. 8-K filing accepted for Dec 3, 2003 Click here. Nov. 24, 2003 - Breakthrough in Detecting Cancerous Tissue via Stokes Shift Emission Spectroscopy Click here. July 16, 2003 - CCNY Receives $6 Million NASA Grant To Enhance Photonics Research Click here. 10-Q SB filed May 31, 2003 Click here. 8-K filing accepted for June 5, 2003 Click here. 8-K filing accepted for April 28, 2003 Click here. additional 8-K filing, March 2003 Click here. January 22, 2003-Strategy and Biography of the THM Group, L.L.C. Click here. 8-K filing accepted for January 22, 2003 Click here. October 2, 2002-CCNY Receives $6 Million NASA Grant To CCNY Center for Optical Sensing and Imaging Click here. Introductory Letter from the Chairman of Mediscience Technology Corporation click here 8-K filing accepted for June 12, 2002 Click here. 10-KSB filing accepted for June 19, 2002 Click here. The following presentation entitled "Optical Biomedical Imaging" describes another light based diagnostic technology developed by Mediscience Technology Corp. This technology is in addition to the fluorescence spectroscopy also developed by Mediscience. Click here. Web Broadcast by Prof. Robert R. Alfano about fluorescence spectroscopy Click here to watch. Prof. Robert R. Alfano Named Fellow of New York Academy Of Sciences, 1999 click here Laser Imaging and Cancer Diagnostics Produced for Breast Cancer and Women�s Health Awareness Day (1998) click here Detecting Cancer Without Surgery click here Advances in Optical Biopsy and Optical Mammography click here Optical Fibers Invention to Aid Medical Diagnostics click here Related Papers By Prof. Alfano click here Introductory Letter from the Chairman of Mediscience Technology Corporation Molecular Biology, firmly established, presents medical investigators with a new viewpoint and a new way of approaching traditional pathology. This extraordinary approach to patient care began in 1953 when DNA structure was demonstrated and continues to surprise with recent DNA discoveries. It is said that Molecular Biology is in essence the study of life itself. It will allow researchers to discover nature's secrets of disease with the ability to examine the normal mechanisms of health and the ways living systems work -- --the predicate for an early understanding of disease formation on a molecular basis. The traditional and Conventional Medical research goal was to understand the response of tissues, organs, and the entire body to the cause of disease. Researchers looked to the reporting by physicians at the bedside of the sick, attempting to understand or gain insight to the causes of disease and ways of combating the symptoms. Today�s Molecular Biology is a total and wonderful departure for the ultimate good. This present explosion of medical knowledge has been matched by equally extraordinary progress in technology and inventions. Approaching medical instrumentation at the molecular and cellular level has merged the efforts of physicists, engineers, and researchers bringing potential benefits to the process of medical discovery and early treatment of disease. Our ten-year relationship with the Research Foundation of City University of New York and the pioneering work of Dr. Robert Alfano is a prime example of such modern medical/engineering synergy. This is an accelerating and fast-moving process, impacted each and every day by new engineering and related science discovery. The challenge to any Company in this field is not just to produce a market entry product but also to keep in step, be able to adapt and change with the stream of improvements effecting or of benefit to its technology. Mediscience�s president feels that the recent partnering with Sarnoff Corporation and our long-standing medical associates (Sloan-Kettering, Yale, New York Medical/Cornell etc.) positions the Company to continually evolve a significant platform technology. Peter Katevatis Esq. Chairman Mediscience Technology . 1/26/2001 New York Academy Of Sciences Announces 1999 Fellows NEW YORK, NY October 6, 1999 � Nineteen distinguished scientists were named 1999 Fellows by the New York Academy of Sciences. They join a select and prestigious community of Academy members honored each year for extraordinary scientific accomplishments and service to the science community and the public. These awards are highly regarded in the international community of science and reflect the Academy�s continuing commitment to excellence, to its 182-year heritage, and to serving its worldwide membership of more than 38,000 scientists, engineers, research physicians, and others deeply concerned about science and technology. The award of Academy Fellow is initiated through nomination by Academy peers. The Board of Governors� Committee on Fellows and Honoree Life Members reviews all nominees and makes its selection based upon the quality and extent of accomplishment and service. Fellows represent all the sectors served by the Academy: biomedical sciences, physical sciences, mathematics, engineering and technology, social science, science and technology policy, and service education. This year�s Fellows are an unusually broad cross-section of excellence in sciences. They include two prominent advocates of public understanding of science, a leader in e-commerce; a scientist who made major contributions to medicines for neuroscience, molecular biology, arthritis, and inflammation; the principal architect of General Electric�s strategic planning system for R & D and a neurologist who is also a best-selling novelist. They represent many distinguished academic institutions, among them Harvard, Princeton, Columbia, The Rockefeller University, Massachusetts Institute of Technology, and the University of Texas at Dallas. A complete list of the Academy�s 19999 Fellows is attached. The New York Academy of Sciences is an independent, non-for-profit organization committed to advancing science, technology, and society worldwide since 1817. For more information, visit our web site at http://www.nyas.org Robert R. Alfano, Distinguished Professor of Science and Engineering, City College of New York, CCNY Jesse H. Ausubel, Senior Research Associate, The Rockefeller University Phaedon Avouris, Manager, Nanometer Scale Science and Technology, IBM Corporation Gerald M. Edelman, Chair, Neurobiology, The Scripps Research Institute Harvey V. Fineberg, Provost, Harvard University Alan Friedman, Director, New York Hall of Sciences D. Frank Hsu, Professor of Computer Science, Fordam University Barabara Petrack, Senior Research Fellow, Dana Research Institute, Drew University Oliver W. Sachs, Neurologist and author George Schillinger, Professor Emertus of Engineering and Management, Polytechnic University Daniel Schutzer, Vice President and Director of External Standards and Advanced Technology, Citibank Suresh P. Sethi, Ashbel Smith Professor of Operations Management, University of Texas at Dallas David E. Shaw, President, D.E. Shaw & Co. Sydel F. Silverman, President, Wenner-Gren Foundation for Anthropological Research Lowell Steele, Vice President (ret.) GE; Tech Planning and Management Consultant; Adjunct Professor Emertus, Polytechnic University Joseph F. Traub, Edwin Howard Armstrong Proffesor of Computer Science, Columbia University Kosta Tsips, Principle Research Scientist, and Founder and Director, Program in Science & Technology for International Security, Massachusetts Institute of Technology Neil de Grasse Tyson, Visiting Research Scientist and Lecturer in Astrophysics, Princeton University; Fredrick P. Rose Director, Hyden Planetarium, American Museum of Natural History George M. Whitesides, Mallincrodt Professor of Chemistry, Harvard University |
Detecting Cancer Without Surgery
Optical Biopsy Technique Arrives at medical Centers
A promising BMDO-founded medical technology is well on its way to commercialization, thanks to the combined efforts of Mediscience Technology Corporation, or MTC (Cherry Hill, NJ), and Dr. Robert Alfano, Director of the institute for Ultrafast Spectroscopy and Lasers (IUSL) at the City College of New York. Developed and patented by Alfano, optical Spectroscopy was featured in the Update, Vol. 2, No. 2, 1992 as a technique for the early diagnosis of cancer in breast and gynecological tissue. Since then, MTC has made progress towards the commercialization of the process, known as optical biopsy due to its ability to test tissue for cancer using light in place of a scalpel. This progress has occurred through the development and clinical testing of a prototype device, as well as preliminary discussion with the FDA concerning the technique. Furthermore, MTC has distributed optical biopsy equipment to medical researchers for exploration of its potential applications in operating rooms and doctors' offices; those that prove worthwhile will be commercialized as well.
First Clinical Uses to Detect Breast and Gynecological Cancers.
Spun-off from the BMDO's Medical Free Electron Laser program, Dr. Alfano's technique exposes suspected tissue to ultraviolet and visible laser or lamp light, causing substances naturally present in the body to fluoresce. The fluorescence spectra is measured and compared a different intensities and wavelengths. Cancerous tissues consistently display different result from benign or normal samples.
This phenomenon enabled Dr. Alfano to develop a diagnostic tool based on light-induced fluorescence. Optical spectroscopy has achieved high accuracy percentages - 96 percent for breast tissue and 87 percent for other gynecological tissue. Now undergoing clinical testing, it could provide a painless, radiation-free alternative to conventional methods of cancer detection in the near future. MTC plans to use the technique for quicker, more accurate PAP tests (tests of gynecological tissue extracted during routine examinations), more accurate needle-core breast screening, and eventually for non-invasive imaging and diagnosis of breast tissue. The company is also equipped with the optical device, to be used for in-situ diagnosis and intra-operative evaluation of ovarian and cervical tissue.
New Uses Also Under Investigation
Dr. Stimson Schantz MD, of the Memorial Sloan Kettering Cancer Center (New York, NY) and Dr. mark Bessler MD, of Columbia Presbyterian's Department of Surgery (New York, NY) are two researchers working with Mediscience's technology. Both are studying optical spectroscopy's effectiveness in the detection of cancer and other abnormalities. Dr. Schantz's research concentrates on the mouth; he hypothesizes that Dr. Alfano's technique will enable earlier detection of both genetic and cellular damage in the region. Such problems could then be treated with preventive measures such as vitamins and behavior alteration. Although it is too early for conclusive results from Dr. Schantz's research, he finds that the light technique "definitely has merit," and is optimistic about the technology's success.
Dr. Bessler is focusing on the use of fluorescence spectroscopy on the colon, esophagus and stomach. He has been using surgical specimens to test the technique, and MTC plans to build a small endoscope for future testing once his initial results are confirmed. Those results has been encouraging, and according to Dr. Bessler enough data should be available within a year or so to start clinical testing, the next step in bringing this application to maturity. In the future, the optical spectroscopy technique could be used as a screening device for general patient checkups, examining several areas of the body without patient discomfort or adverse side effects.
Potential applications of laser or light induced fluorescence are not limited to cancer detection. Dr. James P. Slater, MD and Dr. Mehmet Oz, MD. cardiac surgeons with Columbia Presbyterian are using the method to monitor metabolism and blood flow non-invasively, through a surface probe placed over the heart. When the heart is not getting enough oxygen, the UV light elicits a different fluorescence spectrum, indicating that the anaerobic pathways are being used. The technique could therefore be used during surgery to monitor the heart. The method is currently undergoing intensive research, both on rats and large animals, and Dr. Slater is optimistic about its prospects, he predicts that it will easily be approved for use due to its non-invasive nature.
Even as these applications are examined, the number of potential uses continues to grow - providing material for future testing. The fluorescence spectroscopy technique could be used to distinguish between malignant and benign skin lesions, for instance, along with other potential medical applications related to such varying areas as organ transplants, wound evaluation and "laser welding" of biological tissues. The technology's potential is not limited to only medical applications; the industrial applications market is considerable. According to MTC, all that is required to capitalize on that fact is further research and development, perhaps in conjunction with another commercial partner.
Advances in Optical Biopsy and Optical Mammography
Robert R. Alfano (The New York State Center for Advanced Technology in Ultrafast Photonic Materials and Applications at The City University of New York), Ed.
Optical biopsy and optical Mammography are exciting new techniques that allow investigators to determine whether a tissue is cancerous without using invasive techniques. An analysis of the spectrum light emitted from optically excited tissue allows investigators to detect physical and chemical changes in tissue and determine whether the tissue is normal, benign, or cancerous. Optical biopsy and optical Mammography are emerging applications of science and technology, which may lead to novel diagnostic and therapeutic approaches. Because they are minimally invasive, and use non-ionizing radiation to detect diseases with high sensitivity and accuracy, optical methods have great biological and clinical potential.
click here to contact the publisher
Optical Fibers Invention to Aid Medical Diagnostics
City College researchers have invented a fiber-optic assembly that may have important applications for medical applications for medical diagnostics using Raman and fluorescence spectroscopy.
The invention has received U.S. Patent #6,006,001. The inventors are Professor Robert R. Alfano, Director of CCNY's institute for Ultrafast Spectoscopy and Lasers (IUSL), Dr. Stavros G. Demos and Dr. Gang Zhang. "The miniature size of the fiber-optic assembly makes it well-suited for use inside the working channel on an endoscope and other remote medical, chemical and biological diagnostic instruments, "Dr. Alfano said. He noted that when optical fibers are used to transmit and collect information carried by weak signals, such as Raman or fluorescence generated by a tissue sample, excessive spectral noise arises. "This is because additional Raman and fluorescence signals are produced in the fiber itself from the excitation light, interfering with the transmission of information," he said.
The invention by the CCNY team eliminates this problem by incorporating two different types of very small optical fibers: namely selected dielectric-coatings in the excitation and detection arms of a miniature fiber bundle. "The fiber-optic assembly incorporates filters in an illumination fiber and in a series of light collection fibers on a miniature scale," Dr. Alfano added. "We are very excited about potential medical and other applications for this new development.
CUNY College�s IUSL is part of the New York State Center for Advanced Technology for Ultrafast Photonic Materials and Applications at CUNY, which Dr. Alfano also heads.
Related Papers By Prof. Alfano